Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of Andamertinib Combined With Anlotinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Failed Prior First Line Third Generation EGFR TKI Therapy

NCT07780578 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07780578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07780578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of Andamertinib Combined With Anlotinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Failed Prior First Line Third Generation EGFR TKI Therapy
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2029
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc, locally advanced or metastatic, second-line